Corcept accused in California of stifling Teva’s generic launch

A group of health insurers has filed a lawsuit against Corcept Therapeutics (NASDAQ:CORT) in California, accusing the rare disease drugmaker of blocking Teva Pharmaceutical (NYSE:TEVA) from marketing a generic version targeted at its best-seller Korlym.

In August 2020, the Israeli drugmaker